RT info:eu-repo/semantics/article
T1 TERT amplification a risk stratification marker in papillary thyroid carcinoma, significantly correlated with tumor recurrence and survival
A1 Gil Bernabé, Sara
A1 Feás Rodríguez, Noa
A1 Pérez Riesgo, Enrique
A1 Corraliza Gómez, Miriam
A1 Fra Rodríguez, Joaquín
A1 García-Rostán y Pérez, Ginesa María
K1 TERT amplification
K1 Thyroid cancer
K1 Metastases
K1 Prognosis
K1 Tumor recurrence
K1 Survival
K1 32 Ciencias Médicas
AB Few studies have analyzed the prevalence of TERT amplification in thyroid cancer, showing discrepancies in various top-ics. The impact on tumor recurrence and patient survival in papillary thyroid carcinoma (PTC) remains unknown. Thirteencancer cell lines and 215 tumor samples from 91 patients, who underwent surgery for PTC (41), poorly differentiated thyroidcarcinoma (PDC = 15), or anaplastic thyroid carcinoma (ATC = 35), were analyzed. Clonality, spread with tumor dediffer-entiation or metastatic PTC cells, and coexistence with TERTp, BRAF, RAS, and PIK3CA mutations were also investigated.TERT amplification was found in 17%, 20%, and 17% of the PTC, PDC, and ATC, respectively. It was more frequent infollicular variant PTC and PTC with distant metastases (86%, P = 0.0448). The cell lines HTh74, SW1736, and T242 hadamplification. In PTC, TERT amplification was a subclonal event. The increase in TERT copy number spread in all cases withmetastatic PTC cells. In 67% of the PDC and 100% of the ATC, TERT activation segregated with tumor dedifferentiation.TERT amplification correlated with TERTp mutations in PTC (P = 0.0313) and PIK3CA mutations in ATC (P = 0.0272).TERT amplification significantly correlated with vascular invasion (P = 0.03637), distant metastases at diagnosis and/orfollow-up (P = 0.04482), metachronous distant metastases (P = 0.03131), death patient status (P = 0.000829), stage at diag-nosis (P = 0.01995), and stage III/IV at last follow-up (P = 0.01552). TERT amplification associated independently withtumor-related recurrence and death. Our study shows that PTC can be stratified into clinically prognostic relevant categoriesbased on the presence or not of TERT amplification in the cells.
PB Springer
SN 1046-3976
YR 2025
FD 2025
LK https://uvadoc.uva.es/handle/10324/75937
UL https://uvadoc.uva.es/handle/10324/75937
LA eng
NO Endocrine Pathology, 2025, vol. 36, n. 1.
NO Producción Científica
DS UVaDOC
RD 11-ago-2025